Capricor Craters 67% as FDA Questions Deramiocel Data

Capricor fell roughly 67% after FDA briefing documentsquestioned deramiocel's efficacy days before its advisory committee — and the company's rebuttal is a fight over which statistical analysis plan governs. Webreak down what that means for cell therapy in Duchenne muscular dystrophy, argenx's $2.2 billion all-cash acquisition of Forte Biosciences for the anti-CD122 antibody FB102 in vitiligo and celiac disease, and the abrupt CEO exit at Legend Biotech as competitive pressure builds around Carvykti. Visit us at thepharmacloseout.com.